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Abstract
Background: Androsterone glucuronide (ADTG) concentrations have been suggested as a marker of the effects of
androgens at the target tissue level. As the mechanism for hyperandrogenemia in obese and nonobese polycystic
ovary syndrome (PCOS) may differ, this study compared the different androgen parameters in non-obese compared
to obese women with PCOS, and in normal subjects.
Methods: Eleven non-obese and 14 obese women with PCOS were recruited and compared to 11 control women
without PCOS. Total testosterone, dehydroepiandrosterone sulphate (DHEAS), ADTG, and androstenedione were
analysed using gold standard tandem mass spectrometry, and the free androgen index (FAI) was calculated.
Results: Total testosterone, ADTG and androstendione levels did not differ between non-obese (body mass index
(BMI) ≤25 kg/m2) and obese PCOS (BMI >25 kg/m2) but all were significantly higher than for controls (p < 0.01). The
ADTG to DHEAS ratio was significantly elevated 39 ± 6 (p < 0.01) in obese PCOS in comparison to non-obese PCOS
and controls (28 ± 5 and 29 ± 4, respectively). The free androgen index (FAI) and insulin resistance (HOMA-IR) were
significantly higher in obese PCOS compared to non-obese PCOS and controls (p < 0.01). DHEAS was significantly
higher in the non-obese versus obese PCOS (p < 0.01). All androgen parameters were significantly lower and sex
hormone binding globulin (SHBG) significantly higher in normal subjects compared to those with obese and non-
obese PCOS.
Conclusions: The ADTG:DHEAS ratio was significantly elevated in obese PCOS compared to non-obese PCOS and
controls suggesting that this may be a novel biomarker discriminatory for obese PCOS subjects, perhaps being
driven by higher hepatic 5α reductase activity increasing ADTG formation in these women.
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Background
Polycystic ovary syndrome is one of the most common
endocrine disorders and affects 7–9% of reproductive-
aged women [1–3]. Hyperandrogenism is central to the
diagnosis of PCOS in the NIH, the Rotterdam consensus
and the Androgen excess society [4] criteria, but agree-
ment is still lacking on the best androgen measurement
in women with PCOS who suffer from a high incidence
of acne and hirsutism, reflecting increased androgen
secretion.
With the advent of liquid chromatography tandem
mass spectroscopy the accurate measurement of low
serum levels of androgens, their precursors and their
metabolites is now possible, allowing the role of andro-
gens in PCOS to be studied with sufficient sensitivity
and specificity [5]. Recently it was proposed that the tes-
tosterone to dihydrotestosterone ratio may be used as a
biomarker particularly for those with an adverse meta-
bolic phenotype [6]. Androsterone glucuronide (ADTG)
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reflects adrenal androgen secretion from hepatic 5α-
reductase activity, and to a lesser extent peripheral 5α-
reductase activity, that converts dehydroepiandrosterone
sulphate (DHEAS) to ADTG [7, 8]. Thus, DHEAS and
to a lesser amount DHEA (approximately 20%) are con-
verted to ADTG by hepatic and peripheral 5α-reductase
and therefore the concentration of ADTG will reflect
both DHEAS levels and 5α-reductase activity. ADTG
has been reported to be a more reliable marker for the
effects of androgen at the target tissue level and studies
have shown that ADTG is significantly elevated in hirsute
compared to non-hirsute women with PCOS [9–11]. Pre-
viously ADTG has been measured by immunoassay that
may be inaccurate due to cross-reactivity with other an-
drogen metabolites such as DHEAS [12, 13], circum-
vented by tandem mass spectrometry.
Some studies have reported increased hyperandrogen-
aemia in obese compared with non-obese women with
PCOS [14] suggesting that the mechanism for develop-
ment of hyperandrogenism may differ in these two
groups of subject. The aim of this study was to compare
different androgen parameters of testosterone, DHEAS,
ADTG and androstenedione in nonobese compared to
obese women with PCOS, and compared to control
subjects.
Methods
Eleven nonobese [BMI 22.9 ± 1.4 kg/m2] and 14 age-
matched obese [BMI 36.8 ± 4.8 kg/m2] Caucasian
women with a diagnosis of PCOS based on all three
diagnostic criteria of the Rotterdam consensus, namely
clinical (Ferriman-Gallwey score > 8) and biochemical
evidence of hyperandrogenaemia, oligomenorrhea or
amenorrhoea (cycle length, <21 day or >35 days; <8 cy-
cles per year) and polycystic ovaries on transvaginal
ultrasound. Non classical 21-hydroxylase deficiency,
hyperprolactinemia, and androgen secreting tumours
were excluded by appropriate tests before the diagnosis
of PCOS was made. Eleven Caucasian women with nor-
mal menstrual cycle and no evidence of clinical or bio-
chemical hyperandrogenism were recruited as controls
by advert. All subjects were recruited in Hull. Diabetes
was excluded in all subjects by a 75 g oral glucose toler-
ance test. No subject was on any medication that could
alter insulin resistance at the time of the study or within
the preceding three months of entering the trial. There
was no evidence of non-alcoholic fatty liver disease on
abdominal ultrasound examination. Subjects with PCOS
were recruited from the endocrine clinic at Hull Royal
Infirmary, UK. This was a prospective study that en-
rolled all patients that fulfilled the inclusion and exclu-
sion criteria and as a consequence the 2 groups were not
age matched. All subjects gave their informed consent
and the study was approved by the Hull and East riding
ethics committee.
Fasting venous blood was collected into serum gel
tubes (Becton Dickinson, Cowley, Oxfordshire, UK) at
the same time each day (0800–0900). Samples were sep-
arated by centrifugation at 2000 g for 15 min at 4 °C,
and stored at –20 °C within 1 h of collection.
Laboratory analysis
Before analysis, all the serum samples were thawed and
thoroughly mixed. Serum insulin was assayed using a
competitive chemiluminescent immunoassay performed
on a Siemens Immulite 2000 analyser (Siemens Ltd,
Frimley, UK), using the manufacturer’s recommended
protocol. There was no stated cross-reactivity with pro-
insulin. Plasma glucose was measured using a Synchron
LX 20 analyser (Beckman-Coulter, High Wycombe, UK),
using the manufacturer’s recommended protocol. The
coefficient of variation for this assay was 1.2% at a mean
glucose value of 5.3 mmol/l (94.6 mg/dl). The IR was
calculated using the homeostasis model assessment
(HOMA) method (HOMA-IR = (insulin μIU/mL x glu-
cose mmol/l)/22.5) [14]. Serum testosterone [15], andro-
stenedione [16], DHEAS [7, 8], and ADTG [17] were all
measured by isotope dilution liquid chromatography-
tandem mass spectrometry (Waters Corporation,
Manchester, UK) using fully validated methods (17).
SHBG was measured by chemiluminescent detection on
the Siemens Immulite 2000 analyzer using the manufac-
turer’s recommended protocol. The free androgen index
was obtained as the quotient 100 testosterone/SHBG.
Statistical analysis
Statistical analysis was performed using SPSS for Win-
dows, version 22.0. The data was normally distribution
between individuals and none violated the assumptions
of normality when tested using the Kolmogorov-
Smirnov test and therefore are expressed as mean ± SD.
One way ANOVA was undertaken with post hoc testing
between groups. For all analysis, a two-tailed P < 0.05
was considered to indicate statistical significance.
Results
Baseline parameters of subjects are shown in Table 1.
Obese and non-obese PCOS groups were age matched
and were significantly younger than the control subjects.
Weight did not differ significantly between the nonobese
and control subjects but both differed significantly from
the obese PCOS group.
ADTG and androstendione levels did not differ be-
tween non-obese (BMI ≤25 kg/m2) and obese PCOS
(BMI >25 kg/m2) but both were significantly higher than
for controls (p < 0.01). However, the ADTG to DHEAS
ratio was significantly elevated 39 ± 6 (p < 0.01) in obese
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PCOS in comparison to nonobese PCOS and controls
(28 ± 5 nmol/umol and 29 ± 4 nmol/umol, respectively).
DHEAS was significantly higher in the nonobese versus
obese PCOS and controls (p < 0.01). Both non-obese and
obese PCOS were equally hyperandrogenic as measured
by total testosterone (p = 0.73), but the FAI (p < 0.01)
and insulin resistance (HOMA-IR) (p < 0.01) was signifi-
cantly higher in obese PCOS. HOMA-IR did not differ
between non-obese PCOS and control subjects. All an-
drogen parameters were significantly lower and SHBG
significantly higher in normal subjects (p < 0.01) com-
pared to those with obese and nonobese PCOS.
Discussion
This study showed that using state of the art measure-
ment that the ADTG:DHEAS ratio was significantly ele-
vated in obese PCOS compared to non-obese PCOS and
to controls subjects, whilst the latter two groups did not
differ, suggesting that this may be a novel biomarker and
discriminatory for PCOS in obesity. Thus, in the case of
diagnostic uncertainty, the presence of both obesity a
raised ADTG:DHEAS ratio could help confirm the diag-
nosis of PCOS, and the ratio could be an indirect meas-
ure of 5α-reductase activity that may identify those
individuals whose insulin resistance is having a marked
effect on their androgen metabolism. Total testosterone,
ADTG and androstenedione levels did not differ be-
tween obese and non obese PCOS patients, though all
were significantly higher than that of the control sub-
jects. DHEAS levels were higher in the non-obese PCOS
subjects than obese PCOS and control subjects, data are
in accord with that shown by Silfen and colleagues [6].
The raised DHEAS levels should have reflected in a
higher ADTG levels that derive from DHEAS but this
was not seen and indeed the conversion ratio from
DHEAS was the same as the normal controls. It has
been shown that conversion of DHEAS to ADTG occurs
mainly through hepatic 5α-reductase activity, and to a
lesser extent peripheral 5α-reductase activity [9–11]. It is
reported that hepatic 5α-reductase activity is increased
in insulin resistant states [18] and it can be seen from
the results that the obese PCOS patients were signifi-
cantly more insulin resistant than the non-obese PCOS
patients and the normal controls (the HOMA-IR did not
differ between the non-obese PCOS and normal sub-
jects) suggesting that the increased insulin resistance in
obesity may be driving the hepatic 5α-reductase activity
converting DHEAS to ADTG. The enhanced insulin re-
sistance in obesity was reflected in the decrease in the
SHBG levels particularly in the obese PCOS subjects
resulting in an increased FAI. There is little data on the
role ADTG in PCOS and androgen metabolism, however
this study showing the increased ADTG: DHEAS ratio
in obese PCOS using state of the art measurement
free from assay interference addresses the discrepancy
noted in one study that it was not correlated with
PCOS [8, 18], and with another suggesting that
ADTG levels are increased [13].
It was recently proposed that the testosterone to di-
hydrotestosterone ratio may be used as a biomarker par-
ticularly for those with an adverse metabolic phenotype
[18]. It would be of value to prospectively determine if
the ADTG: DHEAS ratio would add additional value as
an additional biomarker for the metabolic phenotype.
Table 1 Baseline parameters of non-obese and obese patients with PCOS and normal controls (mean ± SD), showing the elevated
androgen levels found in PCOS subjects, the elevated ADTG: DHEAS ratio and increased insulin resistance found for the obese PCOS
patients
Parameters Nonobese
(n=11)
Obese
(n=14)
Controls
(n=11)
p value between
nonobese and
obese PCOS
p value between
obese PCOS and
controls
p value between
nonobese PCOS
and controls
Age (years) 23.3 ± 4.5 26.0 ± 4.1 32.6 ± 4.9 0.13 <0.01 0.01
BMI (kg/m2) 22.9 ± 1.4 36.8 ± 4.8 26.0 ± 4.7 <0.01 <0.01 0.051
Total Testosterone
(nmol/L)
1.7 ± 0.7 1.6 ± 0.7 1.0 ± 0.4 0.73 <0.02 <0.02
SHBG (nmol/L) 42.5 ± 16.3 25.4 ± 10.6 61.4 ± 21.8 <0.01 <0.01 <0.03
FAI 4.3 ± 1.7 7.3 ± 4.4 1.9 ± 1.0 <0.03 <0.01 <0.01
DHEAS (μmol/L) 7.6 ± 2.3 5.5 ± 1.7 3.3 ±1.4 <0.05 <0.01 <0.01
ADTG (nmol/L) 213.7 ± 82.3 216.9 ± 121.7 97.7 ± 52.0 0.9 <0.01 <0.01
ADTG/DHEAS ratio
(nmol/umol)
28 ± 5 39 ± 6 29 ± 4 <0.01 <0.01 0.85
Androstenedione
(nmol/L)
7.3 ± 2.8 6.9 ± 3.6 3.2 ± 1.5 0.73 <0.01 <0.01
HOMA-IR 1.6 ± 0.7 4.4 ± 2.8 1.6 ± 0.7 <0.01 <0.01 1.00
SHBG sex hormone binding globulin, FAI free androgen index, DHEAS dehydroepiandrosterone sulphate, ADTG androsterone glucuronide, HOMA-IR homeostasis
model assessment method for insulin resistance
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PCOS is a condition that encompasses a spectrum of
symptoms and presentations that may vary from one pa-
tient to another. It is still unknown whether non-obese
and obese PCOS share the same pathology or in fact
there may be additional factors, whether external or in-
ternal, that triggers the progression from one condition
to the other. ADTG is significantly elevated in hirsute
compared to non-hirsute women with PCOS and it has
been suggested that ADTG is thought to be a more reli-
able parameter of the effects of androgen at the target
tissue level [19].
Androgen levels were significantly higher in PCOS
compared to controls for total testosterone, FAI,
DHEAS, ADTG and androstenedione in accord with the
studies showing the androgenic burden in PCOS [20]. It
is reported that androgen levels fall with age towards the
menopause though still remain elevated after the meno-
pause. In this study the control patients age were higher
than the obese and non-obese PCOS patients; however,
the estimated decrease in androgens with that age differ-
ence would have been minimal and insufficient to ac-
count for the differences seen.
There is concern that hyperandrogenism is associ-
ated with a more atherogenic phenotype leading to
increase future atherosclerosis in women. Recent
studies have shown that whilst there appears to be a
relationship of total testosterone to intima media
thickness and androstenedione and DHEAS to cardiac
changes, longitudinal analysis showed no association
of total testosterone to subclinical cardiovascular dis-
ease over a 5 year period.
The strengths of this study include well-defined
population of subjects and measurement of androgens
using gold standard tandem mass spectrometry. Des-
pite the very significant androgen changes, nonethe-
less the small number of subjects limited this study
and there is a need to repeat the measures using
stratified weight and age match cohorts particularly
weight matching the control subjects for the obese
and non obese PCOS groups. Additional measure-
ments of DHEA (the second largest source of ADTG)
in blood and for the androstenedione:etiocholanolone
ratio in urine as a marker of 5 alpha reductase would
be useful to evaluate.
Conclusions
The ADTG: DHEAS ratio was significantly elevated in
obese PCOS compared to non-obese PCOS and control
subjects suggesting that this may be a novel biomarker
to identify obese PCOS patients, with ADTG formation
perhaps being driven by higher hepatic 5α reductase ac-
tivity reflecting the increased insulin resistance seen in
the obese PCOS group.
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